Showing 4321-4330 of 6059 results for "".
- Long-Term Mortality in Epidermal Necrolysis Influenced by In-Hospital Complicationshttps://practicaldermatology.com/news/long-term-mortality-epidermal-necrolysis-influenced-hospital-complications/2468372/Epidermal necrolysis (EN) is associated with high in-hospital and post-discharge mortality rates, with comorbidities playing a significant role in outcomes. Researchers for the recent cohort study used French Health System data to characterize mortality and sequelae associated with EN, whi
- Study Explores 'Poppers Dermatitis' From Recreational Drugshttps://practicaldermatology.com/news/study-explores-poppers-dermatitis-recreational-drugs/2468371/Exposure to the chemicals in recreational drugs known as “poppers” could cause dermatitis, George Washington University researchers said in a press release about a study published in the Journal of the Drugs and Dermatology. Poppers are often used by gay men for their euphoric eff
- FDA Approves Otezla for Pediatric Psoriasishttps://practicaldermatology.com/news/fda-approves-otezla-for-pediatric-psoriasis-treatment/2468356/Amgen’s Otezla® (apremilast) has been approved by the U.S. Food and Drug Administration (FDA) for pediatric use in treating moderate to severe plaque psoriasis, making it the first oral option for this condition in children. The approval, which to patients ages 6 and older who weigh at lea
- Study: Excessive Sweating Linked to Sensitive Skinhttps://practicaldermatology.com/news/study-excessive-sweating-linked-sensitive-skin/2468351/A new study indicates a significant connection between primary hyperhidrosis, a condition of excessive sweating, and sensitive skin, where skin overreacts to stimuli like sweat and stress. The study was led by Practical Dermatology Editorial Board member Adam Friedman, MD, FAAD, chair of d
- Epicutis Launches Arctigenin Brightening Treatmenthttps://practicaldermatology.com/news/epicutis-launches-arctigenin-brightening-treatment/2468350/Epicutis announced that it has launched its Arctigenin Brightening Treatment, marking what the manufacturer called a significant shift in skin br
- SEEN Unveils New Conditionerhttps://practicaldermatology.com/news/seen-unveils-new-conditioner/2468329/SEEN Hair Care introduced its new Fragrance-Free Leave-In Conditioner that the company said is safe for sensitive and acne-prone skin and non-comedogenic and non-irritating. “This multitasking leave-in conditioner detangles hair while delivering lightweight hydration plus heat, pollution,
- Study Links Radioactive Iodine Therapy to Increased Melanoma Riskhttps://practicaldermatology.com/news/study-links-radioactive-iodine-therapy-increased-melnoma-risk/2468325/A new study found elevated risk of melanoma and other nonkeratinocyte skin cancers in patients with primary thyroid cancer who received radioactive iodine therapy, particularly in the head and neck region. In the JAMA Network Open article “Development of Melanoma and Other Nonkeratinocyte
- Tralokinumab Data for H&N AD Presented at EADVhttps://practicaldermatology.com/news/tralokinumab-data-hn-ad-presented-eadv/2468323/Nine-month interim data from the TRACE study, showing that tralokinumab/tralokinumab-ldrm reduced the severity of moderate-to-severe atopic dermatitis (AD) in the head and neck region of the body (H&N), were shared through one of LEO Pharma’s five late-breaking oral presentations at the 33rd
- Survey: Majority of Physicians Report Feelings of Burnouthttps://practicaldermatology.com/news/survey-majority-physicians-report-feelings-burnout/2468314/A majority of physicians reported feelings of burnout in 2024, according to a new survey. Researchers for the 2024 Survey of America's Current and Future Physicians, which focuses on the state of physician, resident, and medical student wellbeing, included 1,723 responses and co
- SEEN Hair Care Closes $9 Million in Series A Fundinghttps://practicaldermatology.com/news/seen-hair-care-closes-9-million-series-funding/2468305/SEEN, the award-winning haircare brand developed by dermatologist Iris Rubin, MD, has closed a $9 million Series A funding. The company said in a press release that this investment will “accelerate SEEN's growth as the premier science-backed, clinically-proven beauty brand, which sits at the inte